Dark Canyon Laboratories, LLC

Quick facts

Phase 2 pipeline

• DCL-101 vs Golytely · Oncology
  DCL-101 is a small molecule that targets the KRAS G12C mutation, inhibiting the KRAS protein's ability to promote cancer cell growth.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dark Canyon Laboratories, LLC portfolio CI brief
• Dark Canyon Laboratories, LLC pipeline updates RSS